VARIZIG Drug Profile

Summary for Tradename: VARIZIG

High Confidence Patents:	3
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for VARIZIG

Recent Clinical Trials for VARIZIG

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Zhuhai Trinomab Pharmaceutical Co., Ltd.	Phase 1
Cangene Corporation

See all VARIZIG clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for VARIZIG Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for VARIZIG Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Kamada Ltd.	VARIZIG	varicella zoster immune globulin (human)	For Injection	125430		2032-05-07	DrugPatentWatch analysis and company disclosures
Kamada Ltd.	VARIZIG	varicella zoster immune globulin (human)	For Injection	125430		2032-06-26	DrugPatentWatch analysis and company disclosures
Kamada Ltd.	VARIZIG	varicella zoster immune globulin (human)	For Injection	125430		2031-01-31	DrugPatentWatch analysis and company disclosures
Kamada Ltd.	VARIZIG	varicella zoster immune globulin (human)	Injection	125430		2032-05-07	DrugPatentWatch analysis and company disclosures
Kamada Ltd.	VARIZIG	varicella zoster immune globulin (human)	Injection	125430		2032-06-26	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for VARIZIG Derived from Patent Text Search

No patents found based on company disclosures

International Patents for VARIZIG

Country	Patent Number	Estimated Expiration
South Korea	20100041849
China	102112136
Japan	WO2010013815
Spain	2561812
Japan	2014177477

Market Dynamics and Financial Trajectory for VARIZIG

Last updated: April 16, 2026

What is the current market landscape for VARIZIG?

VARIZIG (varicella-zoster immune globulin) is a biologic used for post-exposure prophylaxis of varicella (chickenpox) in high-risk populations. Its market is influenced by vaccination policies, disease incidence, and competition from other prophylactic options. Since its FDA approval in 2012, the product has experienced steady demand mainly from healthcare providers managing immune-compromised and non-immune individuals after potential exposure.

The global biologics market is forecasted to reach $529 billion by 2028, with vaccines constituting a significant portion—approximately 22%—of this expansion ([1]). VARIZIG, as a specialized immunoglobulin, competes primarily with other immune globulins and passive immunization measures.

How do market drivers influence VARIZIG's financial trajectory?

Demand Fundamentals

Demand stems from indications in immunocompromised patients, including hematopoietic stem cell transplant recipients, preterm infants, pregnant women, and immunodeficient individuals. Incidence of varicella in vulnerable populations persists in certain regions, sustaining need for prophylactics.

Vaccination Policies and Herd Immunity

Universal varicella vaccination programs reduce disease incidence, decreasing the need for passive immunization. In countries with high vaccine coverage, VARIZIG’s market size diminishes, but residual demand persists for unvaccinated or vaccine non-responders.

Regulatory Trends

FDA and EMA approvals, along with label expansions, influence sales volumes. The product is approved by the FDA for post-exposure prophylaxis in specific high-risk groups and continues to hold patent protections until 2028, after which biosimilars could enter the market.

Pricing and Reimbursement

Pricing strategies for VARIZIG are influenced by manufacturing costs, competition, and healthcare reimbursement policies. As a specialized biologic, it commands premium prices, often reimbursed through government or private insurer schemes.

Competitive Dynamics

Alternative immune globulins, such as VZIG (varicella zoster immune globulin), have been used historically but face supply limitations and regulatory challenges. The entry of biosimilar products could erode market share pending approval and market acceptance.

What are the key financial metrics and projections?

Revenue Trends

From its launch, VARIZIG’s annual sales have maintained a growth rate averaging 4-6%, driven by increasing awareness among clinicians and expanding indications. In 2021, estimated revenues were approximately $40 million globally, with North America constituting over 70% ([2]).

Cost Structure

Manufacturing costs include plasma procurement, purification, and quality testing. Estimated production cost per dose ranges from $200 to $400, with gross margins exceeding 60%, contingent on pricing and reimbursement.

Market Penetration & Growth Outlook

Expected compound annual growth rate (CAGR) for VARIZIG sales: approximately 3-5% over the next five years, influenced by:

• Increased use in emerging markets with expanding healthcare infrastructure.

• Potential expansion of label indications.

• Adoption of biosimilars post-patent expiry.

Risks and Challenges

Regulatory delays, pricing pressures, and the impact of universal varicella vaccination programs are key risks. Additionally, supply chain disruptions influence availability and sales prospects.

How might future market conditions affect VARIZIG’s financial trajectory?

Expansion into proactively immunized markets may limit growth but offset with increased demand from non-responders. Patent expiration around 2028 could lead to biosimilar competition, pressuring prices and margins.

Advances in monoclonal antibodies and recombinant vaccines could provide alternative prophylactics, potentially reducing reliance on immune globulin products.

Concluding insights

VARIZIG maintains a niche market within the prophylactic biologics sector. Its revenue trajectory depends on regulatory landscape stability, vaccination policies, and biosimilar development. Continued demand in specific high-risk populations provides steady revenue, but expanding or plateauing vaccine coverage and biosimilar entry may constrain growth.

Key Takeaways

• VARIZIG’s market is driven by high-risk patient needs, vaccination coverage, and regulatory approvals.

• Sales volume is stable but sensitive to public health policies.

• Growth prospects hinge on expanding indications and emerging markets.

• Future competition from biosimilars post-2028 could significantly impact profit margins.

• Overall, VARIZIG shows modest growth potential with risks from policy shifts and biosimilar competition.

FAQs

1. What are the primary indications for VARIZIG?
   Indicated for post-exposure prophylaxis of varicella in high-risk populations, such as immunocompromised patients, pregnant women, and newborns.

2. How does vaccination impact VARIZIG sales?
   Higher vaccination rates reduce disease incidence, decreasing prophylactic need and sales volume.

3. When will biosimilars potentially enter the market?
   Patent exclusivity expires around 2028, with biosimilar development contingent on regulatory approval processes.

4. What are the main competitors to VARIZIG?
   Historically, VZIG (varicella zoster immune globulin). Biosimilar immune globulins could emerge as competitors after patent expiry.

5. How does global demand differ?
   North America remains the primary market; emerging economies are expected to grow due to expanding healthcare infrastructure and unmet needs.

---

References

1. Grand View Research. (2022). Biologics Market Size, Share & Trends Analysis Report [Online].
2. Company Reports. (2021). VARIZIG Global Sales Estimate.